159 related articles for article (PubMed ID: 3480060)
1. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients.
Mukhopadhyaya R; Tatake RJ; Krishnan N; Rao RS; Fakih AR; Naik SL; Gangal SG
J Clin Lab Immunol; 1989 Sep; 30(1):21-5. PubMed ID: 2641790
[TBL] [Abstract][Full Text] [Related]
4. [Experimental study on the antitumor activity of regional lymph nodes during immunotherapy].
Kawata H
Nihon Geka Gakkai Zasshi; 1984 Nov; 85(11):1479-89. PubMed ID: 6521727
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the enhancement of anti-tumor activity in patients with cervical cancer by local administration of OK-432].
Yamada Y; Yamamoto K; Wakita K; Shiraki S; Noda K
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3427-31. PubMed ID: 3789753
[TBL] [Abstract][Full Text] [Related]
6. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
7. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
[TBL] [Abstract][Full Text] [Related]
8. [Interferon production in lymph nodes draining breast carcinoma and its augmentation by OK-432].
Nakajima Y; Akimoto M; Kimura M; Matano S; Hirakawa H; Kasai M
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2766-71. PubMed ID: 2428312
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.
Mickel RA; Kessler DJ; Taylor JM; Lichtenstein A
Cancer Res; 1988 Sep; 48(17):5017-22. PubMed ID: 3409231
[TBL] [Abstract][Full Text] [Related]
10. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden.
Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892
[TBL] [Abstract][Full Text] [Related]
11. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
12. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
[TBL] [Abstract][Full Text] [Related]
13. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
Yoshimura Y; Oka M; Harada T; Inou Y; Saito H; Odagawa T; Matsumoto K
J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
[TBL] [Abstract][Full Text] [Related]
14. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
15. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432.
Wakasugi H; Kasahara T; Minato N; Hamuro J; Miyata M; Morioka Y
J Natl Cancer Inst; 1982 Oct; 69(4):807-12. PubMed ID: 6181282
[TBL] [Abstract][Full Text] [Related]
16. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
[TBL] [Abstract][Full Text] [Related]
17. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers].
Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
19. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432].
Kobayashi G
Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383
[TBL] [Abstract][Full Text] [Related]
20. [Effective mechanisms of BRM, with special reference to induction of autologous tumor cell-killing (ATK) activity by OK-432].
Hoshino T; Uchida A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1277-84. PubMed ID: 3488024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
